|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Laurent Fischer||CEO & Director||922,92k||N/D||1964|
|Ms. Leone D. Patterson M.B.A.||Pres, CFO, Principal Financial Officer & Principal Accounting Officer||914,55k||N/D||1963|
|Ms. Angela Thedinga M.B.A., M.P.H.||Chief Technology Officer||577,96k||N/D||1982|
|Dr. Aaron Osborne MBBS||Consultant||682,4k||N/D||1975|
|Ms. Myesha Lacy||VP of Investor Relations & Corp. Communications||N/D||N/D||N/D|
|Mr. Peter Soparkar J.D.||Chief Legal Officer & Corp. Sec.||N/D||N/D||1971|
|Ms. Dena House||VP of HR||N/D||N/D||N/D|
|Mr. Christopher J. DeRespino||Chief Bus. Officer||N/D||N/D||N/D|
|Ms. Julie Clark M.D.||Acting Chief Medical Officer||N/D||N/D||N/D|
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
L'ISS Governance QualityScore di Adverum Biotechnologies, Inc. al 30 aprile 2021 è 8. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 8; diritti degli azionisti: 8; retribuzione: 8.